Skip to main content
Article thumbnail
Location of Repository

Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial

By Fiona M. Thompson, David W. Porter, Shinji L. Okitsu, Nicole Westerfeld, Denise Vogel, Stephen Todryk, Ian Poulton, Simon Correa, Claire Hutchings, Tamara Berthoud, Susanna Dunachie, Laura Andrews, Jack L. Williams, Robert Sinden, Sarah C. Gilbert, Gerd Pluschke, Rinaldo Zurbriggen and Adrian V. S. Hill
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2005). The global distribution of clinical episodes of Plasmodium falciparum malaria.
    2. Saul A (2002) Progress and challenges for malaria vaccines.
    3. (1986). Research toward malaria vaccines.
    4. (1996). Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine.
    5. (2007). Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge.
    6. (2005). Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites.
    7. (2005). Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
    8. (2004). Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
    9. (2003). Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1.
    10. (2007). Structureactivity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation.
    11. (1992). Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.
    12. (2007). A randomized placebo-controlled phase Ia malaria vaccine trial of two virosomeformulated synthetic peptides in healthy adult volunteers.
    13. (2006). Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
    14. (1986). Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum.
    15. (2005). Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.
    16. (2004). Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction.
    17. (2005). Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.
    18. (1995). The assessment of antibody affinity distribution by thiocyanate elution: a simple dose-response approach.
    19. (2005). Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
    20. (1944). The effect of immunity on the asexual reproduction of Plasmodium brasilianum.
    21. (1987). Vaccination-induced variation in the 140 kD merozoite surface antigen of Plasmodium knowlesi malaria.
    22. (1981). Possible importance of macrophage-derived mediators in acute malaria.
    23. (1992). Tumour necrosis factor-dependent parasite-killing effects during paroxysms in non-immune Plasmodium vivax malaria patients.
    24. (1982). Induction of crisis forms in cultured Plasmodium falciparum with human immune serum from Sudan.
    25. (2002). A proteomic view of the Plasmodium falciparum life cycle.
    26. (2006). A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
    27. (2006). Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
    28. (2006). A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
    29. (1997). A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria.
    30. (2001). Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
    31. (2002). Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.